DRMA News & Events

Dermata Therapeutics files to sell 1.48M shares of common stock for holders

Dermata Therapeutics entered into definitive agreements for the issuance and sale of an aggregate of 2,022,062 shares of common stock, series C warrants to purchase up to 2,022,062 shares of common stock and short-term series D warrants to purchase up to 2,022,062 shares of common stock at a purchase price of $2.04 per share of common stock and accompanying warrants in a private placement priced at-the-market under the rules of the Nasdaq Stock Market. The series C warrants and the series D warrants will have an exercise price of $2.04 per share and will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares issuable upon exercise of the warrants. The series C warrants will expire five years from the effective date of stockholder approval and the series D warrants will expire twenty-four months from the effective date of stockholder approval. The closing of the offering is expected to occur on or about December 29, subject to the satisfaction of customary closing conditions. Company insiders, including the Company's CEO, CFO and certain members of the Company's management team, are participating in the offering. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The gross proceeds from the offering are expected to be approximately $4.1M, prior to deducting placement agent's fees and other offering expenses payable by the Company. The potential additional gross proceeds to the Company from the series C warrants and the short-term series D warrants, if fully exercised on a cash basis, will be approximately $8.3M.

Dermata Therapeutics will soon reveal its new brand name for its over-the-counter skincare business representing its evolution toward a more direct, science-first era of dermatologic innovation. While the name remains confidential until the formal unveiling, the Company is offering a first look at the mission and essence driving this new identity-one created specifically for the community of skincare consumers who expect more from their products, their science, and the companies behind them. The company said, "Dermata's mission is to redefine what's possible in dermatology by melding ancestral wisdom with scientific innovation to create an entirely new approach to the category. Dermata wants to empower people to experience a new form of potency that never comes at the expense of health and wellbeing. Their mission serves as the foundation for the new brand name and its accompanying visual and verbal expression. Dermata's therapies, technologies, and product experiences will be framed through a lens that is honest, confident, and uncompromisingly rooted in quantifiable performance...Dermata will unveil the new brand name and identity in the coming weeks. Additional information, including visual assets, product positioning, and launch-phase communications, will be shared over the coming months. The Company plans to launch its first OTC once-weekly acne kit in the middle of 2026."